Analysts have clear opinions on MRTX.

There are 4 analysts on the Wall offering 12 month price targets for Mirati Therapeutics in the last 3 months. The average price target is $117.50 with a high forecast of $134.00 and a low forecast of $101.00. The average price target represents a 24.21% increase from the last price of $94.60.
Mirati Therapeutics, Inc. (MRTX) is followed by 4 analysts on the street.

Chris Shibutani from Cowen & Co. rates it a Buy.

Similarly, 17 days ago George Farmer of BMO Capital Initiated a Hold with a target of $101.00.

The consensus on the street is null.

What does Mirati Therapeutics, Inc.(MRTX) do ?
Mirati Therapeutics, Inc. is a clinical-stage oncology company, which engages in developing a pipeline of oncology products to treat genetic, immunological and epigenetic drivers of cancer in subsets of cancer patients. Its clinical pipeline consists of glesatinib, sitravatinib and mocetinostat. The company was founded on December 13, 1995 and is headquartered in San Diego, CA.

Mirati Therapeutics, Inc. (MRTX) Insider Trades

Looking for stocks just like MRTX?

Based on Wall Street analyst research, several stocks are similar to MRTX
They are:
– MGNX [Info can be found here: ]
– KPTI [Info can be found here: ]